The authors, after defining the epidemiological field of cardiac decompensation, analyse the physiopathologic grounds which are at the basis of the use of metabolic drugs. In particular they show the bioenergetic processes linked to the bioavailability of ATP have a key role in assuring cardiac contractility both at rest and under effort, and how a significant correlation has been shown between the indexes of the systolic and diastolic function, valued with scintigraphic, echocardiographic and invasive methods, and the contents of ATP, surveyed through endomyocardic biopsies, in decompensated human hearts. A review of the main international studies underlines the favourable effects of the use of the ubidecarenone (CoQ10) in cardiac decompensation therapy. In the end the authors show the data of their own experience of the use of CoQ10 in the treatment of the cardiac decompensation. After giving 100 mg/die of CoQ10 for seven months, there was observed a significant improvement of the echocardiographic indexes of the systolic function, of the cardiothoracic relation, of the subjective symptomatology and the objective reports. Authors conclude by asserting that there exists a rationality for the therapeutic treatment of cardiac decompensation offering new horizons in a pathology whose human and social costs will be more and more important in the future.
|Translated title of the contribution||Effects of ubidecarenone in the treatment of heart failure in the elderly|
|Number of pages||7|
|Journal||Gazzetta Medica Italiana Archivio per le Scienze Mediche|
|Publication status||Published - 1994|
ASJC Scopus subject areas